行情

ARDX

ARDX

Ardelyx
NASDAQ

实时行情|Nasdaq Last Sale

5.69
-0.09
-1.47%
盘后: 5.69 0 0.00% 16:00 03/31 EDT
开盘
5.76
昨收
5.77
最高
5.83
最低
5.37
成交量
74.16万
成交额
--
52周最高
8.82
52周最低
2.100
市值
5.06亿
市盈率(TTM)
-3.8353
分时
5日
1月
3月
1年
5年

分析师评级

6位分析师的综合评级

强力推荐

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测

分析师预测ARDX价格均价为13.00,最高价位15.00,最低价为11.00。

EPS

ARDX 新闻

更多
  • Ardelyx Appoints Onaiza Cadoret-Manier to its Board of Directors
  • PR Newswire · 03/16 14:00
  • Tocagen's Upswing, And Other News: The Good, Bad And Ugly Of Biopharma
  • Seeking Alpha - Article · 03/10 09:36
  • Rock star Growth Puts Ardelyx (NASDAQ:ARDX) In A Position To Use Debt
  • Simply Wall St. · 03/09 13:15
  • Ardelyx (ARDX) Reports Q4 Loss, Tops Revenue Estimates
  • Zacks · 03/06 22:15

所属板块

生物技术和医学研究
-0.26%
制药与医学研究
-0.17%

热门股票

代码
价格
涨跌幅

ARDX 简况

Ardelyx, Inc. is a clinical-stage biopharmaceutical company. The Company's therapeutics focuses on addressing cardiorenal and gastrointestinal (GI) diseases. It operates through the research, development and commercialization of biopharmaceutical products segment. The Company's products line includes cardiorenal portfolio and gastrointestinal portfolio. The Company's cardiorenal portfolio includes two Phase III clinical product candidates, tenapanor in Phase III clinical development for treating hyperphosphatemia in end-stage renal disease (ESRD) patients on dialysis and RDX7675 in Phase III clinical development for treating hyperkalemia in chronic kidney disease (CKD) and heart failure patients. The cardiorenal portfolio includes tenapanor, RDX7675, RDX013 and RDX011. Its gastrointestinal portfolio is led by tenapanor for the treatment of irritable bowel syndrome with constipation (IBS-C). The gastrointestinal portfolio includes tenapanor, RDX8940, RDX011 and RDX023.
展开

微牛提供Ardelyx Inc(NASDAQ-ARDX)的股票价格,实时市场报价,专业分析师评级,深度图表和免费的ARDX股票新闻,以帮助您做出投资决策。